“This reanalysis indicates that patients undergoing molecular testing at laboratories using CAP PT can continue to be confident that their test resul...
BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 protein DLL3 was discovered using OBT&rsq...
In a powerful display of solidarity with breast cancer warriors and patients, Avantor, a leading global supplier of products, services, and solutions for l...
--Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, with $150 million under management, announc...
MDxHealth SA (NASDAQ/Euronext: MDXH), a leading commercial-stage precision diagnostics company, today announced a research collaboration with the Universit...
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (OR...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluatin...
Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more tha...
Bristol Myers Squibb and Samsung Biologics have an existing manufacturing agreement for a commercial antibody cancer drug and have expanded the strategic r...
Located in Sapporo, Japan, Hokkaido University Hospital stands as one of the most prominent medical institutions in the country. Affiliated with Hokkaido U...
The primary objective is to evaluate VISTA as a biomarker to guide patient selection and treatment optimization for VISTA-targeted therapies where no stand...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced a new study as part of the I-SPY 2 trial, sponsored and operated by ...
Genetic Technologies Limited (GTG), a pioneering global leader in genomics-based tests focused on health, wellness, and the battle against serious diseases...
SomaLogic’s SomaScan® platform was used to target 15 markers shared among all cancer types. In a new paper published in Nature's Scientific Repo...
© 2025 Biopharma Boardroom. All Rights Reserved.
